NCI awards $2.3 million to ImaginAb
LOS ANGELES—ImaginAb Inc. was recently awarded $2.3 million in funding from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program to help further develop diagnostic imaging agents for Positron Emission Tomography (PET). The funding will be used over the next two years to further ImaginAb's clinical program. The company's head of preclinical development, Dr. David Ho, will serve as the principal investigator in close collaboration with Dr. David Colcher at the City of Hope. Though PET has continued to evolve as a powerful tool for the clinical management of cancer, several important areas of oncology, such as pancreatic and prostate cancer, still lack effective diagnostic and staging tools.
"These funds from the NCI will be invested alongside ImaginAb resources to help drive our prostate and pancreatic oncology program ahead even more aggressively," said Dr. Christian Behrenbruch, CEO of ImaginAb.